First volunteer dosed in intran asal COVID-19 vaccine clinical trial
Open Orphan PLC (ORPH.L) First volunteer dosed in COVID-19 clinical trial
Open Orphan PLC (ORPH.L) Contract renewal with top-3 pharmaceutical client
Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces a further contract
WORLD FACES COVID-19 “VACCINE APARTHEID”
Even countries that hosted vaccine trials — like Argentina, South Africa, Brazil, and Turkey — will not receive adequate supplies.
Open Orphan PLC (ORPH.L) Rule 19.6(c) Confirmation
RULE 19.6(c) CONFIRMATION WITH RESPECT TO STATED POST-OFFER INTENTIONS WITH REGARD TO HVIVO PLC
Open Orphan PLC (ORPH.L) Successful completion of toxicology study
Successful completion of PrEP Biopharm Toxicology study for respiratory ‘viral mimic’
Open Orphan PLC (ORPH.L) Contract renewal with top-3 pharmaceutical client
Successful extension of contract underpins 2021 revenue growth expectations
4d Pharma PLC (DDDD.L) Joins MJFF-sponsored Parkinson’s study consortium
4D pharma Joins Landmark Parkinson’s Progression Markers Initiative
Gerard J Brandon, CEO of Deepverge PLC (DVRG.L) Interview
Deepverge (formerly Integumen) is a vertically integrated business, collaborating technology platforms with partners in artificial intelligence, clinical research, water technologies, medical device and life science.
Open Orphan PLC (ORPH.L) MHRA approval for nasal COVID-19 vaccine trial
Cathal Friel, Executive Chairman of Open Orphan, said: We are delighted to announce, further to our announcement in July, the Codagenix intranasal, single dose COVID-19 vaccine candidate has received MHRA
Open Orphan PLC (ORPH.L) Venn Life Sciences contract wins
This RNS announces two very exciting deals that our Open Orphan subsidiary Venn Life Sciences has been awarded, from both our Paris office and Breda office in the Netherlands.
N4 Pharma PLC (N4P.L) Formulation Work Update
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to provide the following update on its ongoing
